Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.42 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649287 | 0.80 | KMT2A (0.55) | NAPRTCYP3A4PTGS2KMT2AALDH1A1 | |
| SCHEMBL8823334 | 0.80 | KMT2A (0.55) | NAPRTCYP3A4PTGS2KMT2AALDH1A1 | |
| SCHEMBL888683 | 0.80 | CYP1A2 (0.55) | NAPRTCYP1A2CYP3A4MAOAMAOB | |
| SCHEMBL5162688 | 0.80 | NAPRT (0.48) | NAPRTCYP1A2CYP3A4MAOAMAOB | |
| SCHEMBL82140 | 0.77 | ALDH1A1 (0.58) | CYP1A2CYP3A4KMT2AMEN1ALDH1A1 | |
| SCHEMBL27598315 | 0.77 | CYP1A2 (0.45) | NAPRTCYP1A2CYP3A4MAOAMAOB | |
| SCHEMBL12337833 | 0.77 | CYP1A2 (0.51) | NAPRTCYP1A2CYP3A4MAOAMAOB | |
| SCHEMBL1887807 | 0.77 | CYP1A2 (0.51) | NAPRTCYP1A2CYP3A4MAOAMAOB | |
| SCHEMBL7302432 | 0.77 | CYP1A2 (0.51) | NAPRTCYP1A2CYP3A4MAOAMAOB | |
| SCHEMBL27480368 | 0.77 | CYP1A2 (0.51) | NAPRTCYP1A2CYP3A4MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | claimed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | claimed |
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-1556398-B1 | NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7553826-B2 | Cytarabine monophosphate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070037774-A1 | Cytarabine monophosphate (araCMP) cyclic diesters of 1,3 propane-1-(4-pyridyl) diols that (5'-O-cis-[4-(4-pyridyl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta -D-arabinofuranoside); liver cancer; liver disorders; liver viral infections; activates cytochrome P450; side effect reduction; half-life | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
| US-7151092-B2 | Cytarabine monophosphate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20040092476-A1 | Novel cytarabine monophosphate prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-05-13 | — | — | US | disclosed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092476-A1 | Novel cytarabine monophosphate prodrugs | TYMP, CDA, PNP | NAPRT 160/4885CYP1A2 337/4885CYP3A4 95/4885 |
| US-20070037774-A1 | Cytarabine monophosphate (araCMP) cyclic diesters of 1,3 propane-1-(4-pyridyl) diols that (5'-O-cis-[4-(4-pyridyl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta -D-arabinofuranoside); liver cancer; liver disorders; liver viral infections; activates cytochrome P450; side effect reduction; half-life | TYMP, CDA, PNP | NAPRT 357/4885CYP1A2 107/4885CYP3A4 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.